ClinicalTrials.gg
Not yet recruitingNCT07497074Updated Mar 27, 2026

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

A Phase 2 interventional study of JSKN033 and Platinum in Cervical Cancer, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
192nd of 360
78 · median 90
Started
2026
with 24 others
Phase 2
137 of 455
71 open now
Primary completion
2027-10
later than 177 of 239 live
Registered
434th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 192nd largest by planned enrollment of the 360 interventional ones that give a count, is one of 25 that started in 2026, is one of 137 in phase 2, reaches primary completion later than 177 of the 239 other live ones, and was the 434th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer. It will also learn about the antitumor activity and pharmacokinetic/ pharmacodynamic profiles of this therapy.

Read the detailed description

This is an open-label, multicenter, Phase II clinical study conducted in China to evaluate the safety and efficacy of JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab in patients with advanced cervical cancer. The study consists of two phases: a safety run-in phase and a dose expansion phase. Enrolled subjects are patients with persistent, recurrent, or metastatic cervical cancer who have not received prior systemic therapy for recurrent or metastatic disease. All subjects will receive treatment with JSKN033 + cisplatin/carboplatin ± bevacizumab. All enrolled subjects will continue treatment until meeting any of the following treatment termination criteria: disease progression, intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of informed consent, loss to follow-up, death, early study termination, or other criteria specified in the protocol for treatment termination, whichever occurs first.

03

Conditions studied

  • Cervical Cancer

Keywords

  • JSKN033
  • PD-L1
  • Antibody-Drug Conjugates
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign the form.
  2. Age ≥ 18 years old, male or female.
  3. performance status (ECOG PS) score of 0 or 1.
  4. Expected survival ≥ 3 months.
  5. or cytologically confirmed persistent, recurrent, or (FIGO stage IVB) cervical cancer unsuitable for curative surgery and/or curative radiotherapy, meeting the following criteria:

    1. Pathological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
    2. No prior systemic therapy for recurrent or metastatic cervical cancer.
  6. At least one per 1.1 at baseline.
  7. Agree to provide recently archived or fresh tumor tissue samples.
  8. Adequate organ function.
  9. Female subjects of or male subjects whose partners are of childbearing potential agree to use effective measures. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose.
  10. Be able and willing to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Complicated with other malignant tumors within 3 years before the first dose, except for tumor types that have achieved clinical cure through local treatment with extremely low recurrence risk.
  2. History of brainstem, meningeal , spinal cord metastasis or compression, or carcinomatous meningitis; presence of active .
  3. Screening imaging shows tumor invasion, compression, or occurrence in surrounding important organs or risk of esophagotracheal fistula or esophagopleural fistula, except those judged by the investigator and medical monitor to not affect the patient's enrollment and administration.
  4. Prior treatment with topoisomerase I inhibitors or antibody-drug conjugates containing topoisomerase I inhibitors.
  5. Inadequate of previous therapy.
  6. Presence of the risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia:
  7. Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
  8. Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  9. Gastrointestinal abnormalities with obvious clinical manifestations.
  10. Significant serous effusion.
  11. Active diseases requiring systemic treatment.
  12. Uncontrolled infection.
  13. Toxicity of previous anti-tumor treatment has not fully or partially recovered.
  14. History of allogeneic bone marrow or organ transplantation.
  15. Known allergy to any component of the study drug/platinum, or history of severe allergic reactions to other antibody drugs.
  16. Pregnant and/or lactating women, or planning to become pregnant during the study period.
  17. Known history of mental illness, substance abuse, alcoholism, etc., or other situations that the investigator deems may affect the safety or compliance of the study drug treatment.
  18. Any other previous or current diseases, treatments, or laboratory test abnormalities that the investigator deems may confuse the study results, affect the patient's full participation in the study, or participation in the study may not be in the best interest of the patient.
  19. Local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which may lead to high medical risks and/or uncertainty in survival assessment, such as tumor-related leukemia reaction (white blood cell count > 20×10⁹/L), cachexia manifestations, etc.
  20. Known to bevacizumab or allergy to its components, or the medical conditions affecting its safe use (Note: Applicable only to subjects planned to receive bevacizumab).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Safety run-in dose cohort 1

    JSKN033 in combination with platinum-based chemotherapy ± bevacizumab administered intravenously at dose level 1 according to protocol

    Drug: JSKN033 · Drug: Platinum · Drug: Bevacizumab

  • Experimental
    Safety run-in dose cohort 2

    JSKN033 in combination with platinum-based chemotherapy ± bevacizumab administered intravenously at dose level 2 according to protocol

    Drug: JSKN033 · Drug: Platinum · Drug: Bevacizumab

  • Experimental
    Dose expansion cohort

    JSKN033 in combination with platinum-based chemotherapy ± bevacizumab administered intravenously at a selected dose level

    Drug: JSKN033 · Drug: Platinum · Drug: Bevacizumab

Interventions

  • JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

  • JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

  • JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

06

What researchers measure

Primary outcomes

  1. Frequency and severity of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: 21 days from the first dose

  2. Frequency and severity of Treatment-Related Adverse Events (TRAEs)

    Time frame: 21 days from the first dose

  3. Frequency and severity of Serious Adverse Events (SAEs)

    Time frame: 21 days from the first dose

  4. Objective Response Rate (ORR) as assessed by the investigator and IRC per RECIST 1.1.

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 12 months.

Secondary outcomes

  1. Disease Control Rate (DCR)

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 12 months.

  2. Time to Response (TTR)

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 12 months

  3. Duration of Response (DoR)

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 24 months.

  4. Progression-Free Survival (PFS) as assessed by the investigator and IRC per RECIST 1.1

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 24 months.

  5. Overall Survival (OS)

    Time frame: Assessed at approximately 24 months

  6. Maximum plasma concentration (Cmax) of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  7. Time to Cmax (Tmax) of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  8. Trough concentration (Ctrough) of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  9. Area under the plasma concentration-time curve of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  10. Volume of distribution (Vz/F) of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  11. Elimination half-life (t1/2) and clearance (CL/F) of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  12. Accumulation index of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  13. Mean residence time of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  14. Incidence of anti-drug antibodies (ADA) of JSKN033

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2027, 18 months later.

Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's planned 18 months is below that.

Counting every sponsor, half of 204 studies reached it within 42 months; a quarter within 29 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 27, 2026
StartEst.
Apr 2026
Primary completionEst.
Oct 2027
CompletionEst.
Jun 2028
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07497074
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Mar 27, 2026

Study contacts

Chunyan Lan, Dr.
Contact
lanchy@sysucc.org.cn
086-020-87343009

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JSKN033

Start the discussion